Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells

Stem Cells and Development

Volumn 22, Issue 19, 2013, Pages 2655-2664

  Wilson, George S ^a   Hu, Zenan ^b   Duan, Wei ^c   Tian, Aiping ^a,b   Wang, Xin M ^a   McLeod, Duncan ^d   Lam, Vincent ^a   George, Jacob ^a   Qiao, Liang ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b LANZHOU UNIVERSITY   (China)

^c DEAKIN UNIVERSITY   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; SORAFENIB;

ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ALPHA-FETOPROTEINS; ANTIGENS, CD; ANTIGENS, CD44; ANTIGENS, NEOPLASM; ANTIGENS, THY-1; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GLYCOPROTEINS; HUMANS; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS; NIACINAMIDE; PEPTIDES; PHENYLUREA COMPOUNDS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84884557825     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2012.0703     Document Type: Article

References (41)

1. Yuen M-F, J-L Hou and A Chutaputti. (2009). Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 24:346-353.
2. El-Serag HB and KL Rudolph. (2007). Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576.
3. Villanueva A, P Newell and Y Hoshida. (2010). Inherited hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 24:725-734.
4. Chiba T, K Kita, Y-W Zheng, O Yokosuka, H Saisho, A Iwama, H Nakauchi and H Taniguchi. (2006). Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44:240-251.
5. Ma S, K-W Chan, L Hu, TK-W Lee, JY-H Wo, IO-L Ng, BJ Zheng and X-Y Guan. (2007). Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132:2542-2556.
6. Roskams T. (2006). Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 25:3818-3822.
7. Alison MR, S Islam and S Lim. (2009). Stem cells in liver regeneration, fibrosis and cancer: The good, the bad and the ugly. J Pathol 217:282-298.
8. Zender L, MS Spector,WXue, P Flemming, C Cordon-Cardo, J Silke, S-T Fan, JM Luk, M Wigler, et al. (2006). Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125:1253-1267.
9. Dumble ML, EJ Croager, GCT Yeoh and EA Quail. (2002). Generation and characterization of p53 null transformed hepatic progenitor cells: Oval cells give rise to hepatocellular carcinoma. Carcinogenesis 23:435-445.
10. Hermann PC, S Bhaskar, M Cioffi and C Heeschen. (2010). Cancer stem cells in solid tumors. Semin Cancer Biol 20:77-84.
11. Mikhail S and AR He. (2011). Liver cancer stem cells. Int J Hepatol 486954.
12. Tang Y, K Kitisin, W Jogunoori, C Li, C-X Deng, SC Mueller, HW Ressom, A Rashid, AR He, et al. (2008). Progenitor/stem cells give rise to liver cancer due to aberrant TGF-B and IL-6 signaling. PNAS 105:2445-2450.
13. Tirino V, V Desiderio, F Paino, G Pappacio and M De Rosa. (2012). Methods for cancer stem cell detection and isolation. Methods Mol Biol 879:513-529.
14. Fukuda K, Y Saikawa, M Ohashi, K Kumagai, M Kitajima, H Okano, Y Matsuzaki and Y Kitagawa. (2009). Tumor initiating potential of side population cells in human gastric cancer. Int J Oncol 34:1201-1207.
15. Willan PM and G Farnie. (2011). Application of stem cell assays for the characterization of cancer stem cells. Stem Cell Biol Reg Med Part 4:259-282.
16. Meyerrose TE, P Herrbrich, DA Hess and JA Nolta. (2003). Immune-deficient mouse models for analysis of human stem cells. Biotechniques 35:1262-1272.
17. Hess DA. (2011). Mouse models for studying normal and cancer stem cells. Stem Cell Biol Reg Med Part 4. In: Cancer Stem Cells in Solid Tumors. Allan AL, eds., Humana Press, NY, pp 311-325.
18. Ma I and AL Allan. (2011). The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 7:292-306.
19. Ho DW, ZF Yang, K Yi, CT Lam, MN Ng, WC Yu, J Lau, T Wan, X Wang, et al. (2012). Gene expression profiling of liver cancer stem cells by RNA sequencing. PLoS One 7:e37159.
20. Yang ZF, P Ngai, DW Ho, WC Yu, MNP Ng, CK Lau, MIY Li, KH Tam, CT Lam, RTP Poon and ST Fan. (2008). Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 47:919-928.
21. Liu L-L, D Fu, Y Ma and X-Z Shen. (2011). The power and the promise of liver cancer stem cell markers. Stem Cells Dev 20:2023-2030.
22. Zhu Z, X Hao, M Yan, M Yao, C Ge, J Gu and J Li. (2010). Cancer stem/progenitor cells are highly enriched in CD133 + CD44 + population in hepatocellular carcinoma. Int J Cancer 126:2067-2078.
23. Von Wasielewski R, M Mengel, B Wiese, T Rudiger, HK Muller-Hermelink and H Keipe. (2002). Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a multicenter trial. Am J Clin Pathol 118:675-682.
24. Xin H-W, CM Ambe, DM Hari, GW Wiegand, TC Miller, J-Q Chen, AJ Anderson, S Ray, JE Mullinax, et al. (2013). Labelretaining liver cancer cells are relatively resistant to sorafenib. Gut. [Epub ahead of print]; DOI: 10.1136/gatjnl-2012-303261.
25. Rountree CB, L Mishra and H Willenbring. (2012). Stem cells in liver diseases and cancer: Recent advances on the path to new therapies. Hepatology 55:298-306.
26. Dean M, T Fojo and S Bates. (2005). Tumour stem cells and drug resistance. Nat Rev Cancer 5:275-284.
27. Lee TK, VC Cheung and IO Ng. (2012). Liver tumorinitiating cells as a therapeutic target for hepatocellular carcinoma. Cancer Lett. [Epub ahead of print]; DOI: 10.1016/j.canlet.2012.05.001.
28. Tsuchiya A, H Kamimura, M Takamura, S Yamagiwa, Y Matsuda, Y Sato, M Nomoto, T Ichida and Y Aoyagi. (2009). Clinicopathological analysis of CD133 and NCAM human hepatic stem/progenitor cells in damaged livers and hepatocellular carcinomas. Hepatol Res 39:1080-109O.
29. Yoshikawa S, Y Zen, T Fujii, Y Sato, T Ohta, Y Aoyagi and Y Nakanuma. (2009). Characterization of CD133 + parenchymal cells in the liver: Histology and culture. World J Gastroenterol 15:4896-4906.
30. Lin YH, CJ Huang, JR Chao, ST Chen, SF Lee, JJ Yen and HF Yang-Yen. (2000). Coupling of osteopontin and its cell surface recepto CD44 to the cell survival response elicited by interleukin-3 or granulocyte macrophage colony-stimulating factor. Mol Cell Biol 20:2734-2742.
31. Morrison H, LS Sherman, J Legg, F Banine, C Isacke, CA Haipek, DH Gutmann, H Ponta and P Herrlich. (2001). The NF2 tumor supressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15:968-980.
32. Kim H, XL Yang, C Rosada, SR Hamilton and JT August. (1994). CD44 expression in colorectal adenomas is an early event occurring prior to K-ras and p53 gene mutation. Arch Biochem Biophys 310:504-507.
33. Nagabhushan M, TG Pretlow, YJ Guo, SB Amini, TP Pretlow and MS Sy. (1996). Altered expression of CD44 in human prostate cancer during progression. Am J Clin Pathol 106:647-651.
34. Du L, H Wang, L He, J Zhang, B Ni, X Wang, H Jin, N Cahuzac, M Mehrpour, Y Lu and Q Chen. (2008). CD44 is of functional importance for colorectal cancer stem cells cells. Clin Cancer Res 14:6751-6760.
35. Wright MH, AM Calcagno, CD Salcido, MD Carlson, SV Ambudkar and L Varticovski. (2008). Brca1 breast tumors contain distinct CD44 + /CD24 - and CD133 + cells with cancer stem cell characteristics. Breast Cancer Res 10:R10.
36. Takaishi S, T Okumura, S Tu, SS Wang, W Shibata, R Vigneshwaran, SA Gordon, Y Shimada and TC Wang. (2009). Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27:1006-1020.
37. Endo K and T Terada. (2000). Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: Relationships with tumor grade, clinicopathological parameters, p53 expression, and patient survival. J Hepatol 32: 78-84.
38. Yang ZF, DW Ho, MN Ng, CK Lau, WC Yu, P Ngai, PWK Chu, CT Lam, RTP Poon and ST Fan. (2008). Significance of CD90 + cancer stem cells in human liver cancer. Cancer Cell 13:153-166.
39. Li D, T Mallory and S Satomura. (2001). AFP-L3: A new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 313:15-19.
40. Dontu G, D El-Ashry and MS Wicha. (2004). Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 15:193-197.
41. Park SY, HE Lee, H Li, M Shipitsin, R Gelman and K Polyak. (2010). Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 16:876-887.